Merck & Co builds on Indian partnerships; Lupin to co-market Pneumovax 23
This article was originally published in Scrip
Executive Summary
Merck & Co is building on its partnerships approach in India. It has now formed an alliance with Lupin, India's third-largest drug firm by sales, for its 23-valent pneumococcal polysaccharide vaccine (PPSV), Pneumovax 23.